Table 1. Summary of main findings of included clinical studies involving autologous conditioned serum for the management of osteoarthritis of the hip.

ACS: Autologous Conditioned Serum; VAS: Visual Analog Score; IL-1RA: Interleukin-1 Receptor Antagonist

Author (Reference)	Type of Study	Sample Size	Age and Sex	Treatment	Main Findings
Baltzer et al. [24]	Retrospective, clinical, non-blinded, non-randomized intervention study	119 patients (150 hips)	Age: 62.08±0.71 Females: 51.3% Males: 48.7%	Groups: ACS only; ACS + cortisone; and ACS + cortisone + IL-1RA	Intra-articular administration of ACS in patients with OA of the hip is safe and led to significant improvement in pain (VAS scale) at the 14th-month follow-up compared to the baseline, and additional injections of steroids and IL-1RA did not enhance the treatment effect of ACS alone.
Tassara et al. [25]	Retrospective case report	3 hip patients out of 28 cases	Not provided for hip patients	ACS	Intra-articular administration of ACS in patients with OA of the hip is potentially efficacious in terms of reducing pain (VAS scale) at the sixth-month follow-up compared to the baseline.